A practical reference on Beta anomer: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-04. Anything still debated is marked as such rather than presented as settled.
Small amounts of NMN occur in some foods, including certain vegetables, fruits, and animal products, though the quantities are generally low and variable. Human cells also synthesize NMN internally from nicotinamide and other precursors. Research interest increased after studies examined whether raising NAD+ levels affects metabolism and aging-related pathways in animals. Evidence in humans remains limited and mixed for many outcomes, and questions about effective absorption, tissue delivery, and long-term effects are still open. Regulatory status differs by country, with some markets treating NMN as a supplement ingredient and others restricting its sale.
Nicotinamide mononucleotide, usually shortened to NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide base linked to a ribose sugar that carries a phosphate group. In cells, NMN serves as an intermediate in the salvage pathway that produces nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in many oxidation-reduction reactions, NMN sits near central metabolic processes. The compound is not a drug in most jurisdictions and is discussed mainly in biochemistry and nutrition research.
The term NMN commonly refers to the beta isomer, in which the nicotinamide group is attached to the ribose through a beta-glycosidic bond. Commercial material may be supplied as the free acid or as a salt, such as a sodium salt, which affects molecular weight and water solubility. Related compounds include nicotinamide riboside and NAD+ itself, but these are distinct molecules with different formulas and cellular handling. Laboratory research often uses the beta form because it matches the naturally occurring configuration found in biological systems.
Regulatory treatment varies by country. In the United States, NMN has been marketed as a dietary supplement, but the Food and Drug Administration has stated that it is excluded from the dietary supplement definition because it was authorized for investigation as a new drug before being marketed as a supplement. Other jurisdictions may treat it as a novel food, a supplement, or an unapproved drug ingredient. Import and sale rules can therefore differ substantially.
Quality control for NMN focuses on identity, purity, residual solvents, heavy metals, and microbial limits. Because the molecule can absorb water, moisture content and packaging are relevant to shelf life. Suppliers may provide certificates of analysis, but independent verification is often needed for research or commercial use. The long-term stability of different crystal forms, salt forms, and formulations is not fully characterized in the public literature. Some degradation products and their effects on product performance remain open questions.
| Property | Value | Notes |
|---|---|---|
| Chemical name | beta-Nicotinamide mononucleotide | Free acid and salt forms share the core structure. |
| Molecular formula | C11H15N2O8P | Calculated for the free acid; salt forms add counterions. |
| Molar mass | 334.22 g/mol | Approximate value for the free acid form. |
| Appearance | White to off-white powder | Color and texture can vary with purity and salt form. |
| Solubility | Water-soluble | Typically soluble in aqueous media; less soluble in nonpolar solvents. |
Chemically, NMN is described by the molecular formula C11H15N2O8P and a molecular mass near 334.22 g/mol. The beta anomer has a CAS Registry Number of 1094-61-7. It is typically supplied as a white to off-white powder for laboratory use. The molecule carries a phosphate group and a positively charged nicotinamide ring, giving it polar and water-soluble character. These properties influence how it is detected, purified, and stored in research and analytical laboratories.
Nicotinamide mononucleotide, abbreviated NMN, is a nucleotide composed of nicotinamide, ribose, and phosphate. Its structure links nicotinamide to D-ribose 5-phosphate through a glycosidic bond, placing it in the pyridine nucleotide family. The compound exists in alpha and beta anomeric forms, and the beta form is the one used in NAD+ biosynthesis. NMN is not a protein or a hormone; it is a small water-soluble molecule that occurs in living cells as a metabolic intermediate.
Quality control for NMN materials typically includes appearance, assay, impurity profile, residual solvents, heavy metals, and microbial limits. A certificate of analysis summarizes specified tests, but the underlying methods and laboratory accreditation matter. Regulatory treatment varies by country; NMN is sold as a dietary supplement in some markets, while other jurisdictions restrict its use in foods or classify it differently. Independent verification can reduce risks of mislabeling or substitution. Questions remain about how product purity, storage history, and formulation affect delivered dose in humans.
Solid NMN is a polar, water-soluble nucleotide that can absorb moisture from air. Its phosphate ester is susceptible to hydrolysis, and degradation is faster in aqueous solution, under strongly acidic or alkaline conditions, and at elevated temperatures. For laboratory and commercial handling, the solid is typically kept desiccated, protected from light, and stored frozen. Repeated freeze-thaw cycles can introduce moisture and accelerate breakdown. Stability data for specific formulations should be generated rather than assumed from the parent compound.
== Partial list of peptide hormones in humans == Adrenocorticotropic hormone (ACTH) Adropin Amylin Angiotensin Atrial natriuretic peptide (ANP) Calcitonin Cholecystokinin (CCK) Gastrin Ghrelin Glucagon Glucose-dependent insulinotropic polypeptide (GIP) Glucagon-like peptide-1 (GLP-1) Growth hormone Follicle-stimulating hormone (FSH) Human chorionic gonadotropin (hCG) Insulin Leptin Luteinizing hormone (LH) Melanocyte-stimulating hormone (MSH) Orexin/Hypocretin Oxytocin Parathyroid hormone (PTH) Prolactin Renin Somatostatin Thyroid-stimulating hormone (TSH) Thyrotropin-releasing hormone (TRH) Vasopressin, also called arginine vasopressin (AVP) or anti-diuretic hormone (ADH) Vasoactive intestinal peptide (VIP) Somatotropin (GH1) Gonadotropin Releasing Hormone 1 (GNRH1) Gonadotropin Releasing Hormone 2 (GNRH2) Growth Hormone Releasing Hormone (GHRH) Parathyroid Hormone Like Hormone (PTHLH) Corticotropin Releasing Hormone (CRH) Anti-Müllerian Hormone (AMH) Chorionic Somatomammotropin Hormone 1 (CSH1) Chorionic Somatomammotropin Hormone 2 (CSH2) Pro-Melanin Concentrating Hormone (PMCH) Resistin (RETN)
It was during this early period when Jung was an assistant at the Anatomical Institute at Basel University, that he took an interest in paleoanthropology and the revolutionary discoveries of Homo erectus and Neanderthal fossils. These formative experiences contributed to his fascination with the evolutionary past of humanity and his belief that an ancient evolutionary layer in the psyche, represented by early fossil hominins, is still evident in the psychology of modern humans. Despite showing promise in medicine and almost choosing to specialise in surgery, Jung, to the dismay of his family and professors, decided to become a psychiatrist after reading a Richard von Krafft-Ebing's Textbook of Psychiatry. In December 1900, he moved to Zürich and began as an intern (voluntary doctor) at the Burghölzli psychiatric hospital under the psychiatrist Eugen Bleuler. Bleuler was already in communication with Sigmund Freud and introduced Jung to his work. At Burghölzli, Jung became interested in 'dementia praecox' (former name for schizophrenia, a term that Bleuler came up with). Before this he had mainly been interested in neurosis, but psychotic patients would become his primary concern for the rest of his career. In 1902, on leave from Burghölzli, Jung studied with Pierre Janet in Paris, and later equated his view of the complex with Janet's idée fixe subconsciente. In 1905, Jung was appointed as a permanent 'senior' doctor at Burghölzli and became a lecturer Privatdozent in the medical faculty of Zurich University.
Di Prisco G, Casola L, Giuditta A (1967). "Purification and properties of a soluble reduced nicotinamide-adenine dinucleotide (phosphate) dehydrogenase from the hepatopancreas of Octopus vulgaris". Biochem. J. 105 (2): 455–60. doi:10.1042/bj1050455. PMC 1198331. PMID 4171422. GIUDITTA A, STRECKER HJ (1961). "Purification and some properties of a brain diaphorase". Biochim. Biophys. Acta. 48: 10–9. doi:10.1016/0006-3002(61)90509-1. PMID 13705804. MAERKI F, MARTIUS C (1960). "[Vitamin K reductase, preparation and properties.]". Biochem. Z. 333: 111–35. PMID 13765127. Misaka E, Nakanishi K. "Studies on menadione reductase of bakers' yeast. I. Purification, crystallization and some properties". J. Biochem. Tokyo: 465–471. WOSILAIT WD (1960). "The reduction of vitamin K1 by an enzyme from dog liver". J. Biol. Chem. 235 (4): 1196–201. doi:10.1016/S0021-9258(18)69504-3. PMID 13846011. Sparla F, Tedeschi G, Trost P (1996). "NAD(P)H:(Quinone-Acceptor) Oxidoreductase of Tobacco Leaves Is a Flavin Mononucleotide-Containing Flavoenzyme". Plant Physiol. 112 (1): 249–258. doi:10.1104/pp.112.1.249. PMC 157943. PMID 12226388. Braun M, Bungert S, Friedrich T (1998). "Characterization of the overproduced NADH dehydrogenase fragment of the NADH:ubiquinone oxidoreductase (complex I) from Escherichia coli". Biochemistry. 37 (7): 1861–7. doi:10.1021/bi971176p. PMID 9485311. Jaiswal AK (2000). "Characterization and partial purification of microsomal NAD(P)H:quinone oxidoreductases". Arch. Biochem. Biophys. 375 (1): 62–8. doi:10.1006/abbi.1999.1650. PMID 10683249.
Such methods have been applied for discovering protein interactions on human interactome, specifically the interactome of Membrane proteins and the interactome of Schizophrenia-associated proteins. As of 2020, a model using residue cluster classes (RCCs), constructed from the 3DID and Negatome databases, resulted in 96-99% correctly classified instances of protein–protein interactions. RCCs are a computational vector space that mimics protein fold space and includes all simultaneously contacted residue sets, which can be used to analyze protein structure-function relation and evolution.
Sources: en.wikipedia.org
The peptide bond hydrolysed can be designated -C-aaX in which C is an S-isoprenylated cysteine residue, a is usually aliphatic and X is the C-terminal residue of the substrate protein, and may be any of several amino acids This enzyme belongs to the peptidase family M48.
In May 1968, Bush joined the United States Air Force and was commissioned into the Texas Air National Guard. After two years of training in active-duty service, he was assigned to Houston, flying Convair F-102s with the 147th Reconnaissance Wing out of Ellington Field Joint Reserve Base. Critics, including former Democratic National Committee Chairman Terry McAuliffe, have alleged that Bush was favorably treated due to his father's political standing as a member of the House of Representatives, citing his selection as a pilot despite his low pilot aptitude test scores and his irregular attendance. In June 2005, the Department of Defense released all the records of Bush's Texas Air National Guard service, which remain in its official archives. In late 1972 and early 1973, he drilled with the 187th Fighter Wing of the Alabama Air National Guard. He had moved to Montgomery, Alabama, to work on the unsuccessful U.S. Senate campaign of Republican Winton M. Blount. In 1972, Bush was suspended from flying for failure to take a scheduled physical exam. He was honorably discharged from the Air Force Reserve on November 21, 1974. Bush remains the most recent president to have served in the military.
Another fifteen years were required before new and more sophisticated technologies, united today under the name of genetic engineering, would permit the isolation and characterization of genes, in particular those of highly complex organisms.
Polyendocrine metabolic ovarian syndrome (PMOS) is an endocrine disorder characterized by an excess of androgens produced by the ovaries. It is estimated that approximately 90% of women with PMOS demonstrate hypersecretion of these hormones. The cause of this condition is unknown. Speculations include genetic predisposition; however, the gene or genes responsible for this remain unidentified. The condition may have a hereditary basis. Other possible causes include elevated insulin production. Most cases of PMOS involve insulin resistance. It is thought that adipose tissue dysfunction plays a role in the insulin resistance seen in PMOS. Insulin can induce excess testosterone secretion from the ovaries. A complication associated with polyendocrine metabolic ovarian syndrome is high cholesterol, which is treated with statins. In a meta-analysis, atorvastatin was shown to decrease androgen concentrations in people with hyperandrogenism. Elevated insulin leads to lower production of sex hormone binding globulin (SHBG), a regulatory glycoprotein that suppresses the function of androgens. High blood levels of insulin also work in conjunction with ovarian sensitivity to insulin to cause hyperandrogenemia, the primary symptom of PMOS. Obese individuals may be more biologically inclined to PMOS due to markedly higher insulin. This hormonal imbalance can lead to chronic anovulation, in which the ovaries fail to release mature eggs. These cases of ovulatory dysfunction are linked to infertility and menstrual disturbances.
=== EC 1.14.21 With NADH or NADPH as one donor, and the other dehydrogenated === EC 1.14.21.1: Now EC 1.14.19.64, (S)-stylopine synthase EC 1.14.21.2: Now EC 1.14.19.65, (S)-cheilanthifoline synthase EC 1.14.21.3: Now EC 1.14.19.66, berbamunine synthase EC 1.14.21.4: Now EC 1.14.19.67, salutaridine synthase EC 1.14.21.5: Now EC 1.14.19.68, (S)-canadine synthase EC 1.14.21.6: Now EC 1.14.19.20, Δ7-sterol 5(6)-desaturase EC 1.14.21.7: Now EC 1.14.19.69, biflaviolin synthase EC 1.14.21.8: Now EC 1.14.19.63, pseudobaptigenin synthase EC 1.14.21.9: Now EC 1.14.19.70, mycocyclosin synthase * EC 1.14.21.10: Now EC 1.14.19.71, fumitremorgin C synthase * EC 1.14.21.11: Now EC 1.14.19.72, (–)-pluviatolide synthase * EC 1.14.21.12: Now EC 1.14.19.73, (S)-nandinine synthase *
Sources: en.wikipedia.org
==== Magnetic drug delivery ==== Magnetic nanochains are a class of new magnetoresponsive and superparamagnetic nanostructures with highly anisotropic shapes (chain-like) which can be manipulated using magnetic field and magnetic field gradient. The magnetic nanochains possess attractive properties which are significant added value for many potential uses including magneto-mechanical actuation-associated nanomedicines in low and super-low frequency alternating magnetic field and magnetic drug delivery. Cell imaging Nanoparticles have good biological labeling and sensing because of brightness and photostability; thus, certain self-assembled nanoparticles can be used as imaging contrast in various systems. Combined with polymer cross-linkers, the fluorescence intensity can also be enhanced. Surface modification with functional groups, can also lead to selective biological labeling. Self-assembled nanoparticles are also more biocompatible compared to standard drug delivery systems.
Enishi (Hokkaido) Teishu (Honshu) Iyo (Shikoku) Tsukushi (Kyushu) Ryugu (Okinawa) Like every other nation in the world, Yamato has its own Agents of the Four Seasons, each of whom has the duty to manifest their season in every part of the land. The Agents of Spring and Summer begin their journey on the island of Ryugu then move north, while the Agents of Autumn and Winter begin their journey on the island of Enishi, then head south. The role of "Agent" is bestowed by the deities of the seasons based on the physical, mental and spiritual eligibility of a blood descendant of the first Agent, and the chosen individual cannot in any way oppose their destiny. The bestowal occurs when the previous Agent dies or ceases to be eligible for the role. It is possible for an Agent, due to insufficient preparation or drastic events, to be unable to manifest their season, consequently extending the duration of the previous one. This is the case of the Agent of Spring, Hinagiku Kayo, a 16-year-old girl who was kidnapped by the Insurgents at the age of just 6. As a result, spring hasn't manifested in Yamato for 10 years, and winter, instead of lasting 3 months like the other seasons, has lasted 6 months during this period of time. However, the young Hinagiku has made her return and is now preparing to bring her season back to the nation, accompanied by her guard, Sakura Himedaka. It all begins on February 10th of the year 20 of the Reimei era, on the island of Ryugu.
=== Braintree === Johnson founded Braintree in 2007. The company was 47th on Inc. magazine's 2011 list of the 500 fastest-growing companies and 415th in 2012. That year, Braintree purchased Venmo, an app that allows users to send and receive money from each other electronically, for $26.2 million. By September 2013 the company announced it was processing $12 billion in payments annually, with $4 billion on mobile. Shortly afterward, on September 26, 2013, the company was acquired by PayPal, then part of eBay, for $800 million. Time Magazine published that Johnson walked away from the sale of Braintree Venmo with more than $300 million.
The aerosol or spallation frangible powder produced by impact and combustion of depleted uranium munitions (or armour) can potentially contaminate wide areas around the impact sites, leading to possible inhalation by human beings. The actual level of acute and chronic toxicity of DU is also controversial. Several studies using cultured cells and laboratory rodents suggest the possibility of leukemogenic, genetic, reproductive, and neurological effects from chronic exposure. A 2005 epidemiology review concluded "In aggregate the human epidemiological evidence is consistent with increased risk of birth defects in offspring of persons exposed to DU." A 2021 study concluded that DU from exploding munitions did not lead to Gulf War illness in American veterans deployed in the Gulf War. A 2011 study found elevated levels of uranium in soil and hair samples from Fallujah, Iraq, but it was from slightly enriched uranium instead of DU.
=== Energy intake === 5-HT2C receptor agonists reduce appetite by working on serotonin receptors in a region of the brain called the hypothalamus. Lorcaserin (Belviq) was FDA approved for weight loss but was withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer. Cannabinoid receptor antagonists were developed to treat obesity because researchers noticed that cannabinoid agonists (such as THC, the main pharmacologically active component of cannabis), increased appetite. However, some drugs in this class such as rimonabant were withdrawn or ceased development due to concerns about mental health and suicide. More selective drugs—some are in development that act only in peripheral tissues, not the brain—may be able to achieve this result with fewer adverse effects. GLP-1 agonists such as tirzepatide, semaglutide, and liraglutide slow gastric emptying and also have neurologically driven effects on appetite. It is unknown if GLP-1 agonists or dual/triple agonists of GLP-1 and/or the glucagon or GIP receptors act solely by reducing energy intake or if they also increase energy expenditure. Setmelanotide is an agonist of the melanocortin 4 receptor and is used in people with certain rare genetic conditions that cause obesity. It is less effective and not approved for general obesity.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a nucleotide composed of nicotinamide, ribose, and phosphate. In cells, it is an intermediate in NAD+ biosynthesis.
No, NMN and NAD+ are different molecules. NMN is a precursor that cells can convert into NAD+ through enzymatic steps. NAD+ is a larger dinucleotide that serves as a coenzyme in many reactions.
Nicotinamide riboside, or NR, is another NAD+ precursor but has a different structure. NR lacks the phosphate group present in NMN. Both are studied for their roles in NAD+ metabolism, yet they enter cellular pathways in different ways.
Laboratory samples are often kept cool, dry, and protected from light, with frozen storage used for longer periods. Finished products should follow label instructions and avoid excessive heat or moisture.